These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 17926832

  • 21. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
    Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Peralta S, Prantera C.
    Aliment Pharmacol Ther; 2007 Sep 01; 26(5):747-56. PubMed ID: 17697208
    [Abstract] [Full Text] [Related]

  • 22. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2007 Sep 01; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

  • 23. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
    Mocciaro F, Orlando A, Scimeca D, Cottone M.
    Recenti Prog Med; 2007 Nov 01; 98(11):560-4. PubMed ID: 18044405
    [Abstract] [Full Text] [Related]

  • 24. [Use of infliximab in ulcerative colitis].
    Tilg H, Feichtenschlager T, Knoflach P, Petritsch W, Schöfl R, Vogelsang H, Reinisch W.
    Z Gastroenterol; 2007 Aug 01; 45(8):907-11. PubMed ID: 17701864
    [Abstract] [Full Text] [Related]

  • 25. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB, Irving PM.
    J Gastroenterol Hepatol; 2009 Jul 01; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract] [Full Text] [Related]

  • 26. Management of acute severe ulcerative colitis.
    Doherty GA, Cheifetz AS.
    Expert Rev Gastroenterol Hepatol; 2009 Aug 01; 3(4):395-405. PubMed ID: 19673626
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients.
    Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, Giouleme O, Chatzopoulos D, Kapetanakis N.
    Hepatogastroenterology; 2007 Jun 01; 54(76):1074-9. PubMed ID: 17629042
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.
    Gastroenterol Hepatol; 2008 Dec 01; 31(10):629-32. PubMed ID: 19174078
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb 01; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
    Jakobovits SL, Jewell DP, Travis SP.
    Aliment Pharmacol Ther; 2007 May 01; 25(9):1055-60. PubMed ID: 17439506
    [Abstract] [Full Text] [Related]

  • 34. Use of infliximab in particular clinical settings: management based on current evidence.
    Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A.
    Am J Gastroenterol; 2009 Jun 01; 104(6):1575-86. PubMed ID: 19491875
    [Abstract] [Full Text] [Related]

  • 35. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
    Loftus EV.
    Am J Gastroenterol; 2005 Jul 01; 100(7):1435-8. PubMed ID: 15984960
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
    Breynaert C, Ferrante M, Fidder H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G.
    Am J Gastroenterol; 2011 Apr 01; 106(4):778-85. PubMed ID: 21407184
    [Abstract] [Full Text] [Related]

  • 38. Remicade approved for children with Crohn's disease.
    FDA Consum; 2006 Apr 01; 40(4):6. PubMed ID: 17245830
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.